Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
10.53
+0.01 (0.10%)
At close: Aug 5, 2026, 4:00 PM EDT
10.39
-0.14 (-1.33%)
After-hours: Aug 5, 2026, 7:50 PM EDT
Zevra Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Zevra Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $25. The average 1-year stock price forecast is 137.42% higher than the current stock price, while the lowest is $20 (+89.93%) and the highest is $35 (+232.38%).
Price Target: $25 (+137.42%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Zevra Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Buy Maintains $27 → $24 | Buy | Maintains | $27 → $24 | +127.92% | Jul 27, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $29 → $20 | Buy | Reiterates | $29 → $20 | +89.93% | Jul 27, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 24, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $26 | Buy | Reiterates | $26 | +146.91% | Jul 24, 2026 |
| Roth MKM | Roth MKM | Buy Maintains $13 → $21 | Buy | Maintains | $13 → $21 | +99.43% | Jul 24, 2026 |
Financial Forecast
Revenue This Year
145.72M
from 106.47M
Increased by 36.87%
Revenue Next Year
173.08M
from 145.72M
Increased by 18.77%
EPS This Year
1.23
from 1.35
Decreased by -8.64%
EPS Next Year
1.06
from 1.23
Decreased by -14.46%
EPS and Forward PE are based on non-GAAP adjusted numbers.